

BlueOcean NutraSciences Files Management Cease Trade Order Application

TORONTO, April 25, 2016 – BlueOcean NutraSciences Inc. (the “**Company**”) (TSX-V: BOC) announces today that the filing of its audited annual consolidated financial statements as at and for the years ended December 31, 2015 and 2014 (“**Annual Financials**”), related management discussion and analysis (“**MD&A**”) and applicable officer certifications (together with the Annual Financials and MD&A, the “**Annual Materials**”) will be delayed beyond the filing deadline of April 29, 2016.

On Friday, April 22, 2016, the Company was notified by its auditors that it would not be able to complete the Company’s annual audit (the “**Annual Audit**”) and deliver its Auditor’s Report on the Annual Financials within the prescribed time period. The delay is due to the Corporation having deferred the commencement of the Annual Audit and the concomitant extension of the period normally required to complete the audit procedure with Generally Accepted Auditing Standards. The Company expects to have completed the Annual Audit and be in a position to file the Annual Materials on or before May 27, 2016.

In view of this delay in filing, the Company has applied to the applicable Canadian securities regulatory authorities pursuant to National Policy 12-203 - *Cease Trade Orders for Continuous Disclosure Defaults* (“**Policy 12-203**”) for a management cease trade order (“**MCTO**”), which, if granted, would preclude members of management from trading the Company’s common shares until such time as the cease trade order is no longer in effect.

There can be no assurance that a MCTO will be granted. The applicable regulatory authorities may instead issue cease trade orders against the Company for failure to file its Annual Materials within the prescribed time period. If a MCTO is granted it would generally not affect the ability of persons who are not, or who have not been, directors, officers or other insiders of the Company to trade in the Company’s securities.

The Company confirms that it intends to satisfy the provisions of the alternative information guidelines found in sections 4.3 and 4.4 of Policy 12-203 for so long as it is delayed in filing the Materials. The Company is not aware of any other material information concerning its affairs which has not been generally disclosed.

About BlueOcean NutraSciences:

BlueOcean NutraSciences Inc., a Canadian listed public Company (TSX-V: BOC), is a vertically integrated nutraceutical Company that markets three Omega-3 shrimp oil products under the Pure Polar™ brand and three bulk Omega-3/Astaxanthin shrimp oils and is developing additional specialty oils, gel caps and extended release (XR) Omega-3 tablets from shrimp, fish, krill and algae oil also for the Health and Wellness markets. BlueOcean’s bulk shrimp oils contain high levels of naturally occurring astaxanthin, phospholipids, and omega-3 EPA and DHA. Northern and Pacific AstaShrimp™ bulk oils are targeted at the high value and rapidly growing natural astaxanthin and phospholipid omega-3 markets.

BlueOcean and its JV partner, CMAX Technologies Inc., have developed a process to convert shrimp, krill, algae and other fish oils into Extended Release Tablets. BlueOcean owns 50% of the participating and voting rights in 2453969 Ontario Inc., a joint venture with CMAX Technologies that has developed the extended release omega-3/astaxanthin tablets. 2453969 Ontario Inc. also has a 66.7% ownership in Pure Polar Labs Inc., a Nevada company that sells omega-3 and astaxanthin retail products under the brand Pure Polar™.

BlueOcean's Pure Polar™ Omega-3 Shrimp Oil formulations contain over two times more omega-3 EPA & DHA and 10 times more astaxanthin than typical retail krill oil brands, and contain phospholipids for better absorption of omega-3s. Product details and ordering can be found at:
www.purepolarshrimp.com, Amazon.com, Inboxfitness.com and Bonanza.com

Forward Looking Statements: BlueOcean NutraSciences Inc.

This news release may contain forward-looking statements that are based on BlueOcean's expectations, estimates and projections regarding, among other things, its business, the economic environment in which it operates and in respect of the timing of the filing of any updated disclosure documents. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Gavin Bogle
Chief Executive Officer
416-970-3266

Dil Vashi
Director of Corporate Development
416-859-0909
www.blueoceannutra.ca